UK approves vaccine specific to Omicron strain

Moderna representatives said the shots increase antibody levels against all strains of concern compared to the original vaccine.

In addition, it stimulates a strong neutralizing antibody response to BA.4 and BA.5.

After the UK, the European Medicines Agency is expected to approve the vaccine by the end of August to promptly roll out a booster vaccination programme across the EU from September 9.

However, the vaccine may not be approved for use in the U.S., as authorities have requested a vaccine that prevents the latest variants, BA.4 and BA.5.

While Britain and Europe are looking to protect people quickly before winter arrives, the virus is likely to circulate more aggressively, with the US choosing to wait for companies to develop other vaccines.

This is a gamble that even leading infectious disease experts do not yet know the results of.

The Japanese government is also expected to deploy a new Covid-19 vaccine, specifically preventing Omicron’s BA.5 sub-variant, in early October.

The vaccine will be provided to the elderly, people with underlying medical conditions, who are at risk of severe symptoms after contracting Covid-19.

Younger people can also get vaccinated, depending on how effective the vaccine is.

After a brief lull, since March 7, the epidemic Covid-19 heats up back at many places.

According to the World Health Organization, outbreaks are strong in the Western Pacific region and Europe.

The re-outbreak was mainly caused by two subtype variants Omicron’s BA.4 and BA.5 spread rapidly.

The strain has the ability to bind to cells well, evading immunity, so it is easy to dominate the globe.

However, they do not appear to cause serious symptoms, and hospitalizations and deaths have not increased sharply.

However, they do not appear to cause serious symptoms, and hospitalizations and deaths have not increased sharply.

Please Support Alles Europa News